Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1212594

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1212594

Lymphoma Therapeutics

PUBLISHED:
PAGES: 406 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 5450
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16350

Add to Cart

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Lymphoma Therapeutics Market to Reach $25.2 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Lymphoma Therapeutics estimated at US$14.9 Billion in the year 2022, is projected to reach a revised size of US$25.2 Billion by 2030, growing at aCAGR of 6.8% over the period 2022-2030. Non-Hodgkin Lymphoma (NHL), one of the segments analyzed in the report, is projected to record 6.5% CAGR and reach US$20.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Hodgkin Lymphoma (HL) segment is readjusted to a revised 7.9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $4.1 Billion, While China is Forecast to Grow at 10.9% CAGR

The Lymphoma Therapeutics market in the U.S. is estimated at US$4.1 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.7 Billion by the year 2030 trailing a CAGR of 10.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.6% and 7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Select Competitors (Total 93 Featured):

  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Chugai Pharmaceutical Co., Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Forma Therapeutics, Inc.
  • GlaxoSmithKline PLC
  • Immunomedics, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Seattle Genetics, Inc.
  • Spectrum Pharmaceuticals
  • Transgene SA
Product Code: MCP-6298

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Lymphoma Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
    • Cancer Evolves Into the Global Epidemic
    • Global New Cancer Incidence (In Million) for the Year 2020
    • COVID-19 Extends a Major Setback to the World's Battle Against Cancer
    • Lymphoma: Disease Causes, Risks, Types, Symptoms, Diagnosis & Survival
    • New Cases of Leukemia, Lymphoma and Myeloma in the U.S. for the Year 2020
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Targeted Therapies Grow in Popularity for Treating Lymphoma
    • CT Imaging: The Gold Standard & Workhorse of Lymphoma Diagnoses & Monitoring
    • 'Liquid Biopsy' Rises in Prominence Among All Other Types of Lymph Node Biopsies
    • Advancements in the Field of Genomics Brings Hope for the Development of More Potent Cancer
    • What Are the Approved Drugs for Lymphoma?
    • Artificial Intelligence Helps Speed Up & Automate Lymphoma Diagnosis
    • Global Market for AI in Healthcare (US$ Billion) for Years 2020, 2022 & 2024
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Lymphoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 3: World 18-Year Perspective for Lymphoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Hodgkin Lymphoma (HL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Hodgkin Lymphoma (HL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 6: World 18-Year Perspective for Hodgkin Lymphoma (HL) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma (NHL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Non-Hodgkin Lymphoma (NHL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 9: World 18-Year Perspective for Non-Hodgkin Lymphoma (NHL) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Revlimid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Revlimid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 12: World 18-Year Perspective for Revlimid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Rituxan / MabThera by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Rituxan / MabThera by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 15: World 18-Year Perspective for Rituxan / MabThera by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Imbruvica by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Imbruvica by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 18: World 18-Year Perspective for Imbruvica by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Keytruda by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Keytruda by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 21: World 18-Year Perspective for Keytruda by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Adcetris by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Adcetris by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 24: World 18-Year Perspective for Adcetris by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 27: World 18-Year Perspective for Other Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 28: World Lymphoma Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 31: USA 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 34: USA 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 37: Canada 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 40: Canada 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • JAPAN
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 43: Japan 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 46: Japan 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • CHINA
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 49: China 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 52: China 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • EUROPE
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Lymphoma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 55: Europe 18-Year Perspective for Lymphoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2023 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 58: Europe 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 61: Europe 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • FRANCE
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 64: France 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 67: France 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • GERMANY
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 70: Germany 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 73: Germany 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 76: Italy 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 79: Italy 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • UNITED KINGDOM
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 82: UK 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 85: UK 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 88: Spain 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 91: Spain 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 94: Russia 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 97: Russia 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 100: Rest of Europe 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 103: Rest of Europe 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • ASIA-PACIFIC
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Lymphoma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 106: Asia-Pacific 18-Year Perspective for Lymphoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2023 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 109: Asia-Pacific 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 112: Asia-Pacific 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • AUSTRALIA
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 115: Australia 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 118: Australia 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • INDIA
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 121: India 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 124: India 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 127: South Korea 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 130: South Korea 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • LATIN AMERICA
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Lymphoma Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 139: Latin America 18-Year Perspective for Lymphoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2023 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 142: Latin America 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 145: Latin America 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 148: Argentina 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 151: Argentina 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 154: Brazil 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 157: Brazil 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 160: Mexico 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 163: Mexico 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 166: Rest of Latin America 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 169: Rest of Latin America 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • MIDDLE EAST
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Lymphoma Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 172: Middle East 18-Year Perspective for Lymphoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2023 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 175: Middle East 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 178: Middle East 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 181: Iran 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 184: Iran 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 187: Israel 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 190: Israel 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 193: Saudi Arabia 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 196: Saudi Arabia 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 199: UAE 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 202: UAE 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 205: Rest of Middle East 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 208: Rest of Middle East 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
  • AFRICA
    • Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 211: Africa 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 214: Africa 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030

IV. COMPETITION

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!